Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy

Open access

Abstract

BACKGROUND: No study has evaluated the predictive and prognostic role of CD8 and PD-L1 coexpression in non-small-cell lung cancer (NSCLC). METHODS: We analyzed RNA sequencing and/or immunohistochemistry staining in NSCLC patients from The Cancer Genome Atlas (n = 1016), and 34 metastatic NSCLC samples not treated by immunotherapy as prognostic cohorts. As predictive aspect of CD8 and PD-L1, we used 85 NSCLC patients treated with anti-PD-1. Two validation cohorts were used including 44 NSCLC patients treated with anti-PD-1 and an external cohort with different tumor types. RESULTS: In prognostic cohorts, high CD8A expression was associated with longer OS (p = 0.02), while high CD274 mRNA was associated with poor prognosis (p = 0.05). In predictive cohort, high CD8 expression and CD8A mRNA were associated with longer progression-free survival (PFS) (p = 0.0002). There was no significant association between PD-L1 expression and PFS while high CD274 mRNA was associated with longer PFS (p = 0.009). A combination of CD8A and CD274 was highly predictive of outcome. These results were confirmed in the validation cohorts. This two-genes signature demonstrated similar results compared to gold standard signatures. CONCLUSION: CD8 represents both a prognostic and predictive factor of outcomes, while PD-L1 share different prognostic and predictive roles.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-018-0220-9

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Prognostic role of CD8 and PD-L1 expressions in a control cohort of metastatic NSCLC using IHC. a Box plots showing the CD8 IHC expression respectively for patients with high (Sp142+) or low (Sp142−) expression of Sp142 labeling. b, c Kaplan–Meier estimates for overall survival; patients were stratified according to the CD8 (b), and Sp142 (c) labeling expressions: high expression (CD8+/Sp142+; in red) and low expression (CD8−/Sp142−; in blue). d Kaplan–Meier estimates for overall survival; patients were stratified in two groups: a group with low expression of CD8 labeling (CD8−) and high expression of Sp142 labeling (Sp142+) and a group with the other patients. Cutoffs for low and high expressions were defined with the Cutoff Finder method. *p < 0.05; **p < 0.01; ***p < 0.001; ****: p < 0.0001; ns not significant
Fig. 1 Prognostic role of CD8 and PD-L1 expressions in a control cohort of metastatic NSCLC using IHC. a Box plots showing the CD8 IHC expression respectively for patients with high (Sp142+) or low (Sp142−) expression of Sp142 labeling. b, c Kaplan–Meier estimates for overall survival; patients were stratified according to the CD8 (b), and Sp142 (c) labeling expressions: high expression (CD8+/Sp142+; in red) and low expression (CD8−/Sp142−; in blue). d Kaplan–Meier estimates for overall survival; patients were stratified in two groups: a group with low expression of CD8 labeling (CD8−) and high expression of Sp142 labeling (Sp142+) and a group with the other patients. Cutoffs for low and high expressions were defined with the Cutoff Finder method. *p < 0.05; **p < 0.01; ***p < 0.001; ****: p < 0.0001; ns not significantCC BY · PubMed Central
Fig. 2 Prognostic role of CD8 and PD-L1 expressions in TCGA cohort. a Scatter plot showing the correlation between CD8 mRNA expression and CD274 mRNA expression. b Kaplan Meier estimates for overall survival; patients were stratified according to CD8 (b) and CD274 (c) mRNA expression: high expression (CD8+/CD274+; in red) and low expression (CD8-/CD274−; in blue). d Kaplan–Meier estimates for overall survival; patients were stratified in two groups: a group with low expression of CD8A and high expression of CD274 mRNA (CD8A−/CD274+) and a group with the other patients. e Heat map of genes significantly differentially expressed between patients with low-mRNA CD8 and high-PD-L1 expression, and the other patients. The row side bar represents genes upregulated in the group of interest in blue and genes downregulated in yellow. f Pathway selected through an enrichment analysis performed on the downregulated genes using Enrichr with the KEGG 2016 database. g Pathway classification of the upregulated genes using Enrichr with the KEGG 2016 database. Cutoffs for low and high expressions were defined with the Cutoff Finder method. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significant
Fig. 2 Prognostic role of CD8 and PD-L1 expressions in TCGA cohort. a Scatter plot showing the correlation between CD8 mRNA expression and CD274 mRNA expression. b Kaplan Meier estimates for overall survival; patients were stratified according to CD8 (b) and CD274 (c) mRNA expression: high expression (CD8+/CD274+; in red) and low expression (CD8-/CD274−; in blue). d Kaplan–Meier estimates for overall survival; patients were stratified in two groups: a group with low expression of CD8A and high expression of CD274 mRNA (CD8A−/CD274+) and a group with the other patients. e Heat map of genes significantly differentially expressed between patients with low-mRNA CD8 and high-PD-L1 expression, and the other patients. The row side bar represents genes upregulated in the group of interest in blue and genes downregulated in yellow. f Pathway selected through an enrichment analysis performed on the downregulated genes using Enrichr with the KEGG 2016 database. g Pathway classification of the upregulated genes using Enrichr with the KEGG 2016 database. Cutoffs for low and high expressions were defined with the Cutoff Finder method. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significantCC BY · PubMed Central
Fig. 3 Predictive role of CD8 and PD-L1 expression in a cohort of patients treated with nivolumab. a, b Kaplan–Meier estimates for progression-free survival; patients were stratified according to CD8 IHC (A) and mRNA (b) expression: high expression (CD8+/CD8A+; in red) and low expression (CD8-/CD8A−; in blue). c, d Kaplan–Meier estimates for progression-free survival; patients were stratified according to PD-L1 IHC (c) and mRNA (d) expression: high expression (Sp142+/CD274+; in red) and low expression (Sp142−/CD274−; in blue). e, f Kaplan–Meier estimates for progression-free survival; patients were stratified in two groups: a group with high CD8 and PD-L1 IHC (e) and mRNA (f) expression (IHC: CD8+ Sp142+; mRNA: CD8A+ CD274+), and a group with the other patients. g Pathway selected through an enrichment analysis performed on the upregulated genes using Enrichr with the KEGG 2016 database. Heat map of genes significantly differentially expressed between patients with high mRNA CD8 and PD-L1 expressions and the other patients. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significant
Fig. 3 Predictive role of CD8 and PD-L1 expression in a cohort of patients treated with nivolumab. a, b Kaplan–Meier estimates for progression-free survival; patients were stratified according to CD8 IHC (A) and mRNA (b) expression: high expression (CD8+/CD8A+; in red) and low expression (CD8-/CD8A−; in blue). c, d Kaplan–Meier estimates for progression-free survival; patients were stratified according to PD-L1 IHC (c) and mRNA (d) expression: high expression (Sp142+/CD274+; in red) and low expression (Sp142−/CD274−; in blue). e, f Kaplan–Meier estimates for progression-free survival; patients were stratified in two groups: a group with high CD8 and PD-L1 IHC (e) and mRNA (f) expression (IHC: CD8+ Sp142+; mRNA: CD8A+ CD274+), and a group with the other patients. g Pathway selected through an enrichment analysis performed on the upregulated genes using Enrichr with the KEGG 2016 database. Heat map of genes significantly differentially expressed between patients with high mRNA CD8 and PD-L1 expressions and the other patients. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significantCC BY · PubMed Central
Fig. 4 Validation of predictive role of CD8 and PD-L1 expression in a cohort of patients treated with nivolumab or pembrolizumab. a, b Kaplan–Meier estimates for progression-free survival; patients were stratified according to CD8A (a) and CD274 (b) mRNA expression: low expression (in red) and high expression (in blue). c Kaplan–Meier estimates for progression-free survival; patients were stratified in two groups: a group with high CD8A and CD274 mRNA expression (CD8A+ CD274+) and a group with the other patients. Cutoffs for low and high expressions were defined with the Cutoff Finder method. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significant
Fig. 4 Validation of predictive role of CD8 and PD-L1 expression in a cohort of patients treated with nivolumab or pembrolizumab. a, b Kaplan–Meier estimates for progression-free survival; patients were stratified according to CD8A (a) and CD274 (b) mRNA expression: low expression (in red) and high expression (in blue). c Kaplan–Meier estimates for progression-free survival; patients were stratified in two groups: a group with high CD8A and CD274 mRNA expression (CD8A+ CD274+) and a group with the other patients. Cutoffs for low and high expressions were defined with the Cutoff Finder method. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significantCC BY · PubMed Central
Fig. 5 Benchmarking of CD8/PD-L1 mRNA variables in comparison with other immune signatures. a–c Kaplan–Meier estimates for progression-free survival; patients were stratified according to the value of the linear predictor estimated from the clinical Cox model plus CD8/PD-L1 mRNA (a), IFN signature (b), or EIG signature (c) for predictive cohort: high (blue) or low (red) risk. d ROC curves estimated using the linear predictor of the clinical Cox model plus CD8/PD-L1 mRNA (red), IFN signature (green), or EIG signature (blue) for predictive cohort. For each model, the area under the curve is given in brackets. e–g Kaplan–Meier estimates for progression-free survival; patients were stratified according to the value of the linear predictor estimated from the clinical Cox model plus CD8/PD-L1 mRNA (e), IFN signature (f), or EIG signature (g) for the extern validation cohort: high (blue) or low (red) risk. h ROC curves estimated using the linear predictor of the clinical Cox model plus CD8/PD-L1 mRNA (red), IFN signature (green) or EIG signature (blue) for the extern validation cohort. For each model, the area under the curve is given in brackets. Cutoffs for low and high expressions were defined with the Cutoff Finder method. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significant
Fig. 5 Benchmarking of CD8/PD-L1 mRNA variables in comparison with other immune signatures. a–c Kaplan–Meier estimates for progression-free survival; patients were stratified according to the value of the linear predictor estimated from the clinical Cox model plus CD8/PD-L1 mRNA (a), IFN signature (b), or EIG signature (c) for predictive cohort: high (blue) or low (red) risk. d ROC curves estimated using the linear predictor of the clinical Cox model plus CD8/PD-L1 mRNA (red), IFN signature (green), or EIG signature (blue) for predictive cohort. For each model, the area under the curve is given in brackets. e–g Kaplan–Meier estimates for progression-free survival; patients were stratified according to the value of the linear predictor estimated from the clinical Cox model plus CD8/PD-L1 mRNA (e), IFN signature (f), or EIG signature (g) for the extern validation cohort: high (blue) or low (red) risk. h ROC curves estimated using the linear predictor of the clinical Cox model plus CD8/PD-L1 mRNA (red), IFN signature (green) or EIG signature (blue) for the extern validation cohort. For each model, the area under the curve is given in brackets. Cutoffs for low and high expressions were defined with the Cutoff Finder method. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns not significantCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 176

Metadata

Authors
Fumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., Coudert, B., Arnould, L., Favier, L., Lagrange, A., Ladoire, S., Saintigny, P., Ortiz-Cuaran, S., Perol, M., Foucher, P., Hofman, P., Ilie, M., Chevrier, S., Boidot, R., Derangere, V., & Ghiringhelli, F.
Affiliations
  • Université de Bourgogne (FR)
  • Genomic and Immunotherapy Medical Institute (FR)
  • Institut universitaire de cardiologie et de pneumologie de Québec (CA)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • Centre Georges François Leclerc (FR)
  • Centre Léon Bérard (FR)
  • CHU Dijon Bourgogne (FR)
  • Université Côte d'Azur (FR)
  • Inserm (FR)
Corresponding author
Ghiringhelli, François
Venue
British Journal of Cancer
Published
2018-10
Volume
119
Issue
8
Pages
950-960
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2897283341
Cited by
176
References
49
Citations by year
2026: 9 · 2025: 17 · 2024: 21 · 2023: 29 · 2022: 28 · 2021: 41 · 2020: 23 · 2019: 8
FWCI
6.77
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Funders
  • Institut National Du Cancer
  • Institut Du Cancer de Montréal
  • Institute of Cancer Research
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
CD8, PD-L1, CD8A, non-small cell lung cancer, anti-PD-1 therapy, immunotherapy response prediction, prognostic factors, gene expression signatures, overall survival, progression-free survival, tumor-infiltrating lymphocytes
MeSH terms
Progression-Free Survival, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Retrospective Studies, RNA, Messenger, Biomarkers, Tumor, CD8 Antigens, CD8-Positive T-Lymphocytes, Disease-Free Survival, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. https://app.cochat.ai/papers/10.1038/s41416-018-0220-9
The paper
Fumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., Coudert, B., Arnould, L., Favier, L., Lagrange, A., Ladoire, S., Saintigny, P., Ortiz-Cuaran, S., Perol, M., Foucher, P., . . . Ghiringhelli, F. (2018). Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. British Journal of Cancer. https://doi.org/10.1038/s41416-018-0220-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.